Sareum to Present at BioTrinity 2021 Conference

Sareum to Present at BioTrinity 2021 Conference

Cambridge, UK, 21 June 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that its CEO, Dr Tim Mitchell, will give a company presentation at 10:30am BST today at the BioTrinity 2021 conference.

In his presentation, Dr Mitchell will showcase Sareum’s two proprietary TYK2/JAK1 kinase inhibitor programmes: SDC-1801 targeting autoimmune diseases and the severe inflammatory responses and respiratory symptoms arising from Covid-19 and other viral infections, and SDC-1802 targeting cancers.

The presentation is available to delegates of BioTrinity 2021, and a copy of the slides will be made publicly available on Sareum’s website after the presentation - www.sareum.com. 

About BioTrinity

BioTrinity is a highly regarded biopartnering & investment life sciences conference, that aims to shine a light on new innovation in the life sciences industry and inspire growth and create opportunities for all who attend.

The 2021 event will be delivered in a true hybrid format, and will provide seamless live interaction for delegates, who include early-stage and emerging biotech, medtech and digital health companies, big pharma executives, life sciences investors and service providers.

BioTrinity 2021 will be delivered live in a hybrid format at etc. venues Bishopsgate, London and via a dedicated virtual platform on Monday 21 & Tuesday 22 June in person, with the virtual platform available until Friday 25 June. For more information on the BioTrinity event, please visit www.biotrinity.com.

For further information, please contact: